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Severe hypoglycemia is a feared complication of type 1 diabetes yet few trials have targeted 
prevention using optimized self-management (educational, therapeutic and technological 
support).  We aimed to investigate whether improved awareness and reduced severe 
hypoglycemia, achieved during an intensive RCT, were sustained following return to routine 
care. 
Research Design and Methods 
96 adults with type 1 diabetes (29±12 years duration) and impaired awareness of 
hypoglycemia at five UK tertiary-referral diabetes centers were recruited into a 24-week 2x2 
factorial RCT (HypoCOMPaSS). Participants were randomized to: pump (CSII) or multiple 
daily injections (MDI); and real-time continuous glucose monitoring (RT-CGM) or self-
monitoring of blood glucose (SMBG); with equal education/attention to all groups. At 24 
weeks, participants returned to routine care with follow-up until 24 months, including free 
choice of MDI/CSII; RT-CGM vs SMBG comparison continued to 24 months. Primary 
outcome was mean difference (baseline to 24 months; between groups) in hypoglycemia 
awareness.  
Results 
Improvement in hypoglycemia awareness was sustained (baseline Gold score: 5.1±1.1; 24m: 
3.7±1.9; p<0.0001). Severe hypoglycemia rate was reduced from 8.9±12.8 episodes/person-
year over the 12 months pre-study to 0.4±0.8 over 24 months (p<0.0001). HbA1c improved 
(baseline: 8.2±3.2% (66±12mmol/mol); 24m: 7.7±3.1% (61±10mmol/mol); p=0.003). 
Improvement in treatment satisfaction and reduced fear of hypoglycemia were sustained. 
There were no significant differences between interventions at 24 months.  
Conclusions 
Optimized insulin replacement and glucose-monitoring underpinned by hypoglycemia-
focused structured education should be provided to all with type 1 diabetes complicated by 
impaired awareness of hypoglycemia. 
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Hypoglycemia is one of the most feared complications of type 1 diabetes (1), as it can result 
in collapse, coma, seizures, injury and, in rare instances, sudden death. One in five adults with 
type 1 diabetes have experienced severe hypoglycemia (requiring assistance for recovery (2)) 
in the previous six months, regardless of overall glycemic control (3). Around half of those 
with type 1 diabetes for at least 15 years experience an episode each year (4). Severe 
hypoglycemia is six-fold more common in those with impaired awareness of hypoglycemia 
(5), which affects 20-25% of adults with type 1 diabetes (3, 6), rising to almost 50% after 25 
years (1).   
Randomized clinical trials (RCTs) of continuous subcutaneous insulin infusion (CSII) pump 
therapy and continuous glucose monitoring (CGM) have demonstrated that technological 
approaches can help prevent severe hypoglycemia (7, 8), albeit without improving awareness 
of hypoglycemia.  However, studies are short-term (typically 6 months) and it is unclear how 
much of the observed benefit is due to increased education/attention provided alongside the 
active technological intervention.  Indeed, much of the evidence to date for sustained 
reduction (at least one year) in severe hypoglycemia and restoration of hypoglycemia 
awareness comes from studies investigating the impact of structured type 1 diabetes education 
(9) or targeted hypoglycemia-focused psycho-educational intervention (10, 11). 
In the 24-week HypoCOMPaSS RCT, we demonstrated that improved hypoglycemia 
awareness and prevention of recurrent severe hypoglycemia is possible in a high-risk 
population of adults with long-standing type 1 diabetes without worsening overall glycemic 
control (12). We compared insulin pumps (CSII) with multiple daily injections (MDI); and 
adjuvant real-time continuous glucose monitoring (RT-CGM) with conventional self-
monitoring of blood glucose (SMBG) – importantly, with equal education/attention for all 
groups irrespective of randomization. We found no difference in outcomes at 24 weeks by 
insulin delivery or glucose monitoring modality.  
Following 24-week RCT completion, participants returned to routine clinical care with 6-
monthly data collection until 24 months. While participants were able to change insulin 
delivery modality at 24 weeks, the RT-CGM vs SMBG randomized comparison continued to 
24 months. Our aim in the current study was to determine whether the improved awareness 
and prevention of recurrent severe hypoglycemia previously seen across all intervention 
groups at 24 weeks was sustained to 24 months.  
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Research Design and Methods 
Study design and participants 
We have reported elsewhere the study protocol (13) and 24-week RCT results (12). The 
protocol (13) was approved by a central Research Ethics Committee and the Medicines and 
Healthcare products Regulatory Agency, with independently-chaired Trial Steering 
Committee and Data Monitoring and Ethics Committee oversight. All participants provided 
written informed consent.  
In summary, HypoCOMPaSS was a multicenter, 24-week, 2x2 factorial study at five UK 
tertiary referral diabetes centers providing structured education in type 1 diabetes with 
specialist expertise in the management of hypoglycemia and the use of CSII/RT-CGM 
technologies. Eligible participants were aged 18-74 years with C-peptide-negative type 1 
diabetes and impaired awareness of hypoglycemia, confirmed by Gold score ≥4 (6). 
In addition to previously documented baseline and 24-week visits, all participants were asked 
to return at 12, 18 and 24 months for data collection. Participants prospectively recorded 
episodes of severe hypoglycemia. Before each visit, participants underwent 7 days’ blinded 
CGM (Medtronic iPRO). 
Randomisation and masking 
Using a web-based system, and stratified by baseline HbA1c (< and ≥8% (64 mmol/mol)) and 
by center, participants were allocated randomly on an equal allocation basis to one of four 
groups: MDI (insulin aspart/glargine) with SMBG; MDI with SMBG and RT-CGM; CSII 
(insulin aspart) with SMBG; CSII with SMBG and RT-CGM. Allocation sequence was 
generated by an individual not otherwise involved in participant recruitment. Neither 
participants nor investigators were blind to study allocation. 
Procedures 
After baseline assessment, all participants attended a brief (1-2 hour), education session in 
small groups or one-to-one, guided by a standardized workbook (13) . In summary, the aim 
was to facilitate reflection on personalized factors associated with dangerous hypoglycemia 
with formulation of individualized plans to prevent further significant events while 
maintaining overall glycemic control. The session was structured around the four points (N, 
E, S, W) of ‘my hypo compass’ to: Never delay hypoglycemia treatment; establish times of 
Extra risk; recognise Subtle hypoglycemia symptoms; and be Wary about detecting and 
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preventing nocturnal hypoglycemia. Beyond this session, all participants received equivalent 
support including 4-weekly follow-up visits throughout the RCT.  
At the end of the 24-week RCT, participants returned to routine clinical care without further 
study-related attention/support beyond 6-monthly data collection. All had the option of 
switching insulin delivery modality within the context of UK clinical guidance, given 
confirmed problematic hypoglycemia at baseline (14). Decision to change insulin delivery 
modality was not dictated by study design or influenced by study investigators. Those 
randomized to RT-CGM continued to be provided with sensors providing the potential for 
uninterrupted use for a further 18 months (24 months in total).  Those randomized to SMBG 
continued without access to RT-CGM.  
Outcomes 
All RCT outcome measures have been reported in detail elsewhere (13). The primary 
outcome was difference (between baseline and 24 months, and between randomized groups) 
in hypoglycemia awareness determined by Gold score (6).  
Pre-specified secondary outcomes were differences (as above) in hypoglycemia awareness 
(assessed by Clarke questionnaire (15) and HypoA-Q Impaired Awareness scale score) (16); 
severe hypoglycemia rate and proportion affected; biochemical hypoglycemia (identified by 
blinded CGM profile: percentage time with glucose ≤3 mmol/l); overall glycemic control 
(HbA1c); total daily insulin dose, body weight; and patient-reported outcomes, primarily fear 
of hypoglycemia (Hypoglycemia Fear Survey II: HFS-II) (17) and satisfaction with diabetes 
treatment (Diabetes Treatment Satisfaction Questionnaire: DTSQ) (18).   
Safety endpoints were hospital admissions, diabetic ketoacidosis and infections related to 
insulin delivery and glucose sensor sites.   
Follow-up for all primary and secondary outcome measures was planned to 24-months post-
randomization. 
Statistical analysis 
The primary trial comparison was CSII vs MDI and RT-CGM vs SMBG alone, as reported 
elsewhere (12). Long-term analyses were based on pre-planned secondary outcomes at 24-
month follow-up in addition to changes between baseline and 24 months in the overall study 
population. Per-protocol analyses were planned based on knowledge of participant behavior 
and undertaken for insulin delivery modality, given that participants had freedom to choose 
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after the 24-week RCT (MDI only throughout, switched with use of both MDI and CSII over 
the 24 months, or CSII only throughout) and for RT-CGM use (<50 versus ≥50% of days in 
study). Data analysis took the form of a complete case analysis. Missing data were not 
deemed sufficient to justify imputation of values. Secondary long-term outcome analyses 
were exploratory, based mainly on descriptive and graphical representations. Hypothesis 
testing for the primary comparison was pre-planned, with significance levels set at α=0.05 
throughout. Data are presented as mean±SD or proportions. 24-month data were analysed 
using t-test or Chi-Square. Statistical analysis was undertaken using STATA (versions 12 & 
14). 
Role of the funding source 
Neither Diabetes UK nor the providers of study devices had any role in study design, data 
collection, analysis, interpretation, writing, or in the decision to submit for publication.  
Results 
Participants 
Ninety-six adults with type 1 diabetes and impaired awareness of hypoglycemia were 
randomized. At baseline, mean±SD age was 49±12 years and diabetes duration 29±12 years, 
35 (36%) were men, 97% were using MDI (3% using CSII), and none had previously used 
RT-CGM. Full demographic and clinical characteristics were similar in all groups, published 
previously (12).  
At 24 months, 76 (79%) were retained (Supplemental Figure 1). Baseline characteristics in 
those lost to follow-up were comparable to those retained for the study duration (Table 1). 
Thirty-nine (78%) participants randomized to MDI were retained at 24 months, with 10 
(26%) still using MDI. Thirty-seven (80%) participants randomized to CSII were retained, 
with 25 (68%) still using CSII. Thirty-nine (81%) participants randomized to SMBG alone 
were retained at 24 months, and all were still using SMBG alone as commencement of RT-
CGM during study follow-up was precluded. Thirty-seven (77%) participants randomized to 
RT-CGM plus SMBG were retained, with 11 (30%) still using RT-CGM at study completion.  
Long-term outcomes 
The improvement in hypoglycemia awareness attained during the RCT irrespective of 
randomized intervention (12) was sustained in the overall study population throughout the 
post-RCT follow-up (Table 2). Maintained benefit at 24 months was confirmed by significant 
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reductions in Gold, Clarke and HypoA-Q Impaired Awareness scale scores compared to pre-
intervention baseline. In parallel, the significantly reduced rate of severe hypoglycemia 
attained during the RCT was sustained during long-term follow-up, with ≤20% of participants 
experiencing events over each 6-month period (Table 2).   
Comparing severe hypoglycemia over the 24-month follow-up with the 12-month period prior 
to randomization confirmed a 95% reduction in annualized rate from 8.9±12.8 to 0.4±0.8 
episodes per person-year (p<0.0001) (Figure 1). Over the 24-month follow-up, 36% of 
participants were affected versus 92% over the 12 months pre-study. All who experienced 
severe hypoglycemia events during the study had reported severe hypoglycemia within the 12 
months pre-study. In those who experienced severe hypoglycemia over the 24-month follow-
up, annualized rate was reduced to 1.5±1.0 episodes per person-year. Only five (5%) 
participants experienced >2 severe hypoglycemic events/person-year, compared with 56 
(58%) over the 12 months pre-study. Comparing consequences of severe hypoglycemia over 
the 24-month follow-up with the 12 months pre-study: 8% vs 32% of participants required 
glucagon administration 7% vs 33% paramedic assistance and 2% vs 6% hospital 
attendance/admission.  
HbA1c at 24 months was significantly lower than at baseline (Table 2). In participants with 
baseline HbA1c ≥8% (64 mmol/mol), glycemic control improved incrementally throughout 
the 24-month study period, while in those with baseline HbA1c <8%, glycemic control was 
not ‘relaxed’, with average remaining <7.5% (58 mmol/mol) (Figure 1).  
Previously observed improvements in treatment satisfaction, perceived frequency of 
hypoglycemia and hyperglycemia, and fear of hypoglycemia were sustained throughout the 
24-month study (Table 2).  
Although the reduction in clinically important (19) biochemical hypoglycemia (interstitial 
glucose ≤3 mmol/L) achieved in the RCT (Baseline: 53±63 min/24 h vs 24 weeks: 24±56 
min/24 h) was maintained throughout post-RCT follow-up (Table 2), this was no longer 
statistically significant at 24 months (37±56 min/24h). The significant reduction in mean total 
daily insulin dose seen within the RCT, equating to 8 units per participant, was sustained at 
24 months with weight unchanged throughout the study (Table 2). 
Insulin delivery comparison 
At 24 months, there was no significant difference in hypoglycemia awareness between those 
initially randomized to CSII and those to MDI (Supplemental Table 1). Reductions in severe 
 8 
hypoglycemia, HbA1c, daily insulin dose and other secondary endpoints were all equivalent 
in the MDI versus CSII group intention-to-treat analysis.  
Having completed the primary 24-week RCT on randomized intervention, participants were 
free to change insulin delivery modality supported by their clinical team on return to routine 
care without any further study-specific support. Nevertheless, all participants remained in 
specialist centers and those transitioning to CSII received additional training and support 
according to established center-specific practice. Per-protocol analysis confirmed comparable 
outcomes in those who used both MDI and CSII over the 2-year study period to those using 
only MDI or CSII (Supplemental Table 1). The greater satisfaction with treatment (DTSQ 
total) observed with CSII compared to MDI at 24 weeks was no longer apparent at 24 months 
(Supplemental Table 2). Although statistical analyses were not deemed appropriate due to low 
numbers, possible associations were seen between improved hypoglycemia awareness, 
reduced severe hypoglycemia and lower hypoglycemia worry in those choosing to remain on 
MDI throughout. Higher HbA1c in those who remained on MDI was also noted 
(Supplemental Table 2).  
Monitoring regimen comparison 
At 24 months, there were no significant differences between those randomized to SMBG 
alone and those to RT-CGM, in terms of hypoglycemia awareness, severe hypoglycemia or 
any secondary outcomes (Supplemental Table 1). 
Despite provision of sensors for uninterrupted RT-CGM use, only 11 (30%) of the RT-CGM 
group continued to use this technology throughout the full 24-month follow-up. Exploratory 
per-protocol analysis of the 14 participants with complete RT-CGM usage data compared 
those using RT-CGM <50% versus ≥50% of the time (Supplemental Table 2). Although small 
numbers precluded statistical analysis, there were no severe hypoglycemic events and a trend 
towards improved hypoglycemia awareness observed in those using RT-CGM <50% of the 
time. As in the primary RCT, higher RT-CGM use was associated with a trend towards less 
biochemical hypoglycemia. 
Comparing outcomes between all participants (Table 2), those randomized to RT-CGM 
(Supplemental Table 1) and the sub-group who used this monitoring modality throughout the 
study (Supplemental Table 2) suggests no differences between groups, with the exception of 
fear of hypoglycemia, which appears particularly low in those who used RT-CGM throughout 
the 24 months.    
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Safety 
Over the 24-month study, six episodes of ketoacidosis required hospitalisation, five during 
CSII and one during MDI. All resolved without sequelae. Twelve other severe adverse events 
(CSII: n=7; MDI: n=5) were unrelated to trial interventions. These included episodes of 
acute-angle closure glaucoma, pneumonia, gastroenteritis, fractured radius and pre-existing 
neuropathic foot ulceration requiring intravenous antibiotics.  
Conclusions 
Improved hypoglycemia awareness and reduced rate of severe hypoglycemia observed in a 
short-term intensive RCT was maintained at 24 months after return to routine clinical care. 
This was paralleled by a clinically meaningful 0.5% reduction in mean HbA1c, sustained 
improvement in treatment satisfaction and reduced fear of hypoglycemia. This study 
demonstrates that a brief educational intervention with intensive support over 24 weeks leads 
to benefits sustained over 24 months in a high-risk cohort with long-standing type 1 diabetes 
and impaired awareness of hypoglycemia. It confirms that avoiding severe hypoglycemia 
does not need to be achieved at the expense of higher overall glucose levels.  
HypoCOMPaSS provides further evidence that structured education and support should 
underpin interventions targeting impaired awareness of hypoglycemia in type 1 diabetes. This 
corroborates a meta-analysis concluding that structured education reduces rates of severe 
hypoglycemia (20). Most previous studies have adopted a before-and-after design with small 
numbers and short-term follow-up. Only two RCTs with at least 12-month follow-up have 
specifically recruited participants with impaired awareness of hypoglycemia. In both the 
HyPOS and HAATT studies (10, 21), reduction in severe hypoglycemia was greater, over 18 
and 31 months respectively, in those who received the psycho-educational program than in 
the control group. Unlike HypoCOMPaSS, neither reported improved HbA1c. It is striking 
that substantial reductions in total daily insulin dose were observed throughout the current 24-
month study without any protocol-driven insulin dose titration regimen beyond the 24-week 
RCT.   
Participants had completed standardized type 1 diabetes education in insulin dose adjustment 
according to glucose levels and carbohydrate intake prior to study recruitment and all 
received the ‘my hypo compass’ psycho-educational intervention prior to randomization. The 
absence of a group not receiving hypoglycemia-focused structured education is a limitation, 
discussed previously (12), although the durability of the impact in this high-risk group prone 
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to recurrent severe hypoglycemia is reassuring. Sustained effective behavior change enabled 
through a short-term psycho-educational intervention, despite withdrawal of trial-specific 
input at 24 weeks, supports cost-effectiveness for wider implementation although formal 
health economic analysis was not undertaken. An important caveat is that all participants 
remained under specialist care, in keeping with national guidance recommending this for 
those with a history of problematic hypoglycemia (22). A qualitative process evaluation is 
underway to explore facilitators of long-term benefit, in addition to a further RCT comparing 
standard medical management of impaired awareness of hypoglycemia with and without the 
‘my hypo compass’ psycho-educational program.     
Although previous studies have reported lower severe hypoglycemia rates with CSII 
compared to MDI (23), only the current RCT has provided equivalent education, 
attention/support to both groups in addition to optimized basal analog MDI. As all 
participants fulfilled national criteria for pump therapy (24) at study recruitment, those 
randomized to MDI were aware that they could switch to CSII at the end of the 24 week RCT 
and 57% did so supported by their usual clinical team. In parallel, 30% of those randomized 
to CSII switched to MDI. This crossover (anticipated and supported by the study protocol) 
occurred despite the RCT demonstrating no differences in biomedical outcomes, fear or 
perceived frequency of hypoglycemia between insulin interventions. At 6 months, satisfaction 
with treatment had been higher in those randomized to pump but was comparable at 24 
months, after 18 months of preferred insulin delivery. This is consistent with the overall 
findings that benefits comparable to CSII (including treatment satisfaction) can be achieved in 
individuals favoring MDI. A trend towards lowest mean HbA1c in those using CSII 
throughout was seen, although numbers remaining on MDI were small. Recently, the 
REPOSE trial reported comparable biomedical benefits for those randomized to CSII or MDI 
with equivalent structured education and attention/support (25). While supporting the 
conclusion that sustained benefits can be achieved in long-standing type 1 diabetes 
complicated by impaired awareness of hypoglycemia regardless of chosen insulin delivery 
modality, the a priori, pragmatic decision to allow cross-over after 24 weeks in 
HypoCOMPaSS was a potential limitation, as it precluded definitive RCT comparison of 
MDI versus CSII over the full 24-month follow-up period. Further work is needed to establish 
the relative benefits of CSII over optimized MDI and individual participant drivers to switch 
from MDI to CSII and vice versa during the post-RCT follow-up are being explored through 
the qualitative process evaluation noted above.  
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In the current 24-month randomized comparison of SMBG with RT-CGM, both interventions 
were equally effective in restoring hypoglycemia awareness and preventing severe 
hypoglycemia without compromising average glycemic control. This may reflect the specific 
focus on augmenting conventional finger-prick glucose monitoring with targeted post-
prandial and 4am testing, in contrast to standard clinical practice (26). It is important to note 
that, although at 24 weeks in the HypoCOMPaSS study >95% of participants were using low-
glucose alerts and 75% stated that RT-CGM was beneficial in preventing severe 
hypoglycemia, more than two thirds were no longer using this modality at 24 months. This is 
a limitation  as previous trials have reported higher sensor use, together with an association 
between greater use and optimal impact (26, 27). Mirroring the current study, decreased use 
and discontinuation over time has been a concern in the non-trial community setting, with 
>40% of RT-CGM users on enrolment to the US T1D Exchange Clinic Registry having 
stopped using the technology 12 months later (28). Discomfort wearing and difficulties 
inserting sensors were the commonest reasons for cessation. Ongoing improvements in 
reliability and accuracy have been associated with greater use (27, 29). The factors underlying 
cessation of RT-CGM in HypoCOMPaSS are being further investigated through qualitative 
analysis of participant semi-structured interviews. 
Relatively few participants used RT-CGM ≥50% of the time, but 38% of these continued to 
experience severe hypoglycemia, whereas none of those using RT-CGM <50% of the time 
experienced any events. It may be that those at highest risk of severe hypoglycemia are those 
who used RT-CGM virtually uninterrupted as a ‘lifeline’ to provide ‘technological 
hypoglycaemia awareness’ (20). 
Median sensor use of nearly 90% was attained in a recent 16-week crossover trial evaluating 
RT-CGM in 52 participants with type 1 diabetes and impaired awareness of hypoglycemia on 
MDI or CSII therapy (30). Biochemical hypoglycemia and number of severe hypoglycemia 
events was lower during the RT-CGM period. This was associated with reduced fear of 
hypoglycemia, a possible association with continued RT-CGM in the current study.  
Using subcutaneous sensor-based ‘flash glucose monitoring’ (where readings over the 
preceding 8 hours are obtained by bringing a reader in close proximity to the sensor), 
significant reduction in biochemical hypoglycemia has been achieved in an RCT comparison 
with conventional SMBG among adults with type 1 diabetes and optimal HbA1c (≤7.5%) 
(31). High participant satisfaction and system utilization (>90%) was reported, though time 
with glucose <3.1 mmol/L remained substantial even in the intervention arm (3.3%). 
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Participants with ‘diagnosed hypoglycemia unawareness’ were excluded from the trial and 
there was no reduction in fear of hypoglycemia. An 8 week pilot RCT comparing RT-CGM 
with flash glucose monitoring in participants with impaired hypoglycemia awareness and/or 
recent severe hypoglycemia achieved reduced biochemical hypoglycemia only in the RT-
CGM group (32).  
The automated CGM-driven low glucose suspend (LGS) feature was not activated in the 
HypoCOMPaSS study. This is an important limitation, as greater reduction in nocturnal 
hypoglycemia compared to CSII and RT-CGM without LGS has been reported with sensor-
augmented pumps enabling automated suspension of insulin delivery for two hours on 
detection of low interstitial glucose (33). Reduced severe hypoglycemia in those randomized 
to sensor augmented pump therapy including LGS compared to those receiving CSII alone 
has been reported in young people with relatively short duration type 1 diabetes (8). Access to 
this combination technology has recently been approved by the FDA and NICE (24). 
Recovery of hypoglycemia awareness has not been reported in other trials of RT-CGM (with 
(7, 8) or without (30) LGS), possibly because a psycho-educational component was not 
included. Reversal of hypoglycemia-associated autonomic failure leading to restored 
awareness (34) may have required even greater reduction in time spent with low glucose 
levels, as absolute avoidance of biochemical hypoglycemia has not yet been attained (35). In a 
detailed prospective study of 11 participants with impaired awareness of hypoglycemia who 
used RT-CGM for >70% of the time over 18 months, questionnaire-reported hypoglycemia 
awareness improved with a reduction in severe hypoglycemia incidence but only a modest 
increase in endogenous glucose production in response to experimental hypoglycemia 
demonstrating that physiological counter-regulation remains impaired (36). Taken together, 
existing study findings underline the complex biopsychobehavioral components of 
hypoglycemia recognition and successful self-management (37), suggesting that reliance on 
RT-CGM without heightened attendance to personal cues may lead to reduced mindfulness 
and recognition of hypoglycemia symptoms, leading to continued high risk of severe 
hypoglycemia during any periods ‘off sensor’. Analysis of associations with persisting 
impaired awareness of hypoglycemia despite participation in the current study with its 
primary goal of biochemical hypoglycemia avoidance are planned.  
A weakness of this study is that only 79% of participants completed full post-RCT follow-up, 
with only 58% completing 24-month hypoglycemia awareness Gold score. However, the 
baseline characteristics of those completing the study were comparable to those lost to follow-
 13 
up, and all outcomes were stable from 6 months (with much higher participant retention) 
through all intermediate time-points to 24 months. It could be argued that recall of severe 
hypoglycemia at baseline may not provide the best comparator for the data collected 
prospectively during the 24-month follow-up. Good correlation between retrospective and 
prospective recording of severe hypoglycemia over 12 months has been confirmed but with a 
tendency to under-reporting overall rate when relying on retrospective recall (38).  
In conclusion, brief structured education in addition to informed support in active insulin dose 
self-adjustment underpinned by targeted self-monitoring of blood glucose leads to sustained 
falls in severe hypoglycemia rates in those at high risk. These should be provided, regardless 
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Figure 1. Severe hypoglycemia rate (Panel A) and HbA1c (Panel B) at baseline and 
during the 24-month study.  
Annualised rate of severe hypoglycemia in the overall study population was 20 times lower 
during the 24-month study compared with the 12 months prior to randomization (mean±SD; 
*p<0.0001 using paired t-test with complete pairs only (n=96 baseline; n=69 at 24 months)) 
(Panel A). HbA1c reduced incrementally over the 24-month study in those with baseline 
HbA1c ≥8% (64 mmol/mol) and remained optimal in those with baseline HbA1c <8% (64 
mmol/mol) (Panel B).  
 
Supplemental Figure 1. Flow diagram showing number of participants allocated at 
random to each intervention, completing the 24-week RCT and completing 24-month 
follow-up.  
Numbers using MDI and CSII during the RCT and post-RCT follow-up are shown. No 
participants randomized to SMBG commenced RT-CGM throughout the 24-month study and 
RT-CGM provision was not withdrawn from any participant randomized to RT-CGM 
(although not all continued active use, with 11 (30%) confirmed active users of this 
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Figure 1. Severe hypoglycemia rate (Panel A) and HbA1c (Panel B) at baseline and 
during the 24-month study.  
Annualised rate of severe hypoglycemia in the overall study population was 20 times lower 
during the 24-month study compared with the 12 months prior to randomization (mean±SD; 
*p<0.0001 using paired t-test with complete pairs only (n=96 baseline; n=69 at 24 months)) 
(Panel A). HbA1c reduced incrementally over the 24-month study in those with baseline 
HbA1c ≥8% (64 mmol/mol) and remained optimal in those with baseline HbA1c <8% (64 
mmol/mol) (Panel B).  
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Table 1 – Baseline characteristics of participants retained at 24 months and those lost to follow-up 
 Retained at 24 months  
(n=76) 
Lost to follow-up by month 
24 (n=20) 
Age, years 49.4±12.3 (n=76) 45.5±11.4 (n=20) 
  Median (IQR) 50.5 (41 to 59) 46 (39 to 50.5) 
Female 48 (63%) (n=76) 13 (65%) (n=20) 
Diabetes duration (years) 29.2±12.6 (n=75) 27.6±11.4 (n=20) 
  Median (IQR) 30 (21 to 37) 25 (19.5 to 36.5) 
Hypoglycemia awareness   
    Gold score 5.0±1.2 (n=76) 5.2±1.0 (n=20) 
       Median (IQR)  5 (4 to 6)  5 (4.5 to 6) 
    Clarke score 5.0±1.4 (n=69) 4.7±1.9 (n=18) 
       Median (IQR) 5 (4 to 6) 4.5 (3 to 7) 
    HypoA-Q ‘Impaired Awareness’ scale 13.5±3.3 (n=72) 13.1±3.7 (n=20) 
      Median (IQR) 14 (11.5 to 16) 14 (11 to 16) 
Severe hypoglycemia (12 months pre-study)   
    Annualised rate per person/year 9.013.9 (n=76) 8.3±7.4 (n=20) 
      Median (IQR) 3.5 (1 to 7.5) 7.5 (2.8 to 13) 
    Proportion affected (n (%)) 68 (89%) (n=76) 20 (100%) (n=20) 
HbA1c, mmol/mol 65±11 (n=76) 70±14 (n=19) 
Weight, kg 74.9±14.7 (n=76) 74.2±12.3 (n=19) 
Total daily insulin dose, u/kg 0.7±0.2 (n=75) 0.6±0.2 (n=19) 
Biochemical hypoglycemia, % time 
interstitial glucose ≤3mmol/L 
3.64.2 (n=75) 4.25.2 (n=19) 
Satisfaction with diabetes treatment: DTSQ   
    Total satisfaction 25.4±5.5 (n=76) 23.8±6.1 (n=19) 
    Perceived frequency of hyperglycemia 3.7±1.4 (n=76) 3.8±1.1 (n=19) 
 Perceived frequency of hypoglycemia 3.8±1.2 (n=76) 3.5±1.5 (n=19) 
Fear of hypoglycemia: HFS-II   
    Total 55.9±25.7 (n=74) 66.9±25.1 (n=20) 
    Behavior 23.0±10.6 (n=74) 26.5±13.8 (n=20) 
    Worry 33.2±17.2 (n=76) 40.4±15.5 (n=20) 
Data are meanSD or n (%) unless stated otherwise. 
Number with available data denoted by n number in parentheses.  











Table 2 – Overall study population: hypoglycemia awareness, severe hypoglycemia, biomedical and patient-reported outcomes at baseline and every 6 months 
through to 24-month endpoint  
 Baseline Month 6             
(RCT endpoint) 
Month 12 Month 18 Month 24       
(Study endpoint) 
P-value 
(Baseline vs M24) 
Hypoglycemia awareness       
    Gold score 5·1±1·1 (n=96) 4·1±1·6 (n=85) 3·9±1·7 (n=75) 3·5±1·8 (n=63) 3·7±1·9 (n=56) <0·0001 (n=56) 
      Median (IQR) 5 (4 to 6) 4 (3 to 5) 4 (2 to 5) 3 (2 to 5) 4 (2 to 5)  
    Clarke score 4·2±1·6 (n=87) 3·2±1·7 (n=80) 3·0±2·0 (n=66) 2·9±2·1 (n=61) 2·5±2·1 (n=50) <0·0001 (n=47) 
      Median (IQR) 5 (4 to 6) 3 (2 to 4) 3 (1 to 5) 3 (1 to 5) 2 (0 to 4)  
    HypoA-Q ‘Impaired Awareness’ 13·4±3·4 (n=92) 9·1±4·2 (n=84) 8·6±4·5 (n=74) 8·1±4·7 (n=65) 8·4±5·0 (n=57) <0·0001 (n=55) 
      Median (IQR) 14 (11 to 16) 9.5 (6 to 12) 8.5 (5 to 12) 8 (5 to 12) 9 (4 to 11)  
Severe hypoglycemia       
    Annualised rate per person/year 8·913·4 (n=96) 0·8±1·8 (n=90) 0·3±0·8 (n=86) 0·2±0·8 (n=73) 0·7±2·0 (n=70) <0·0001 (n=70) 
      Median (IQR) 4 (2 to 7) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0)  
    Proportion affected (%) 77 (n=96) 20 (n=90) 14 (n=86) 12 (n=75) 17 (n=76) 0·02* (n=76) 
HbA1c, mmol/mol 66±12 (n=95) 65±10 (n=89) 65±12 (n=74) 63±10 (n=63) 61±10 (n=72) 0·003 (n=72) 
Weight, kg 74·7±14·2 (n=95) 75·3±13·6 (n=87) 75·9±13·7 (n=84) 75·1±13·7 (n=69) 75·2±13·4 (n=74) 0·93 (n=74) 
Total daily insulin dose, u/kg 0·64±0·23 (n=94) 0·53±0·17 (n=87) 0·53±0·16 (n=73) 0·55±0·14 (n=50) 0·54±0·15 (n=51) <0·0001 (n=51) 
Biochemical hypoglycemia, % time 
interstitial glucose ≤3mmol/L 
3·74·4 (n=94) 1·7±3·9 (n=83) 2·33·6 (n=55) 2·74·5 (n=59) 2·64·1 (n=55) 0·13 (n=54) 
Satisfaction with diabetes treatment: 
DTSQ 
      
 Total satisfaction 25·1±5·6 (n=95) 30·3±5·1 (n=84) 31·6±4·2 (n=78) 31·8±4·3 (n=65) 31·1±4·8 (n=56) <0·0001 (n=56) 
 Perceived frequency of hyperglycemia 3·7±1·3 (n=95) 3·1±1·2 (n=84) 2·9±1·2 (n=78) 2·8±1·4 (n=65) 3·1±1·3 (n=57) 0·0003 (n=57) 
 Perceived frequency of hypoglycemia 3·7±1·3 (n=95) 2·7±1·2 (n=84) 2·7±1·1 (n=77) 2·8±1·4 (n=65) 2·7±1·3 (n=57) 0·0001 (n=57) 
Fear of hypoglycemia: HFS-II       
    Total 58·3±25·8 (n=94) 44·9±24·3 (n=87) 39·8±21·8 (n=60) 35·1±21·1 (n=58) 40·3±26·6 (n=47) <0·0001 (n=46) 
    Behavior 23·8±11·4 (n=94) 20·4±10·1 (n=87) 20·2±10·0 (n=64) 17·1±8·6 (n=58) 19·3±11·2 (n=49) 0·001 (n=47) 
    Worry 34·7±17·1 (n=96) 24·4±16·5 (n=87) 20·2±15·0 (n=67) 18·4±15·2 (n=65) 21·6±17·3 (n=52) <0·0001 (n=52) 
Data are meanSD unless stated otherwise. Number with available data denoted by n number in parentheses.  
Severe hypoglycemia: Annualised rates are based on the 6 months prior to the stated time-points. 
DTSQ: Diabetes Treatment Satisfaction Questionnaire; HFS II: Hypoglycemia Fear Survey II  
P-values compare month 24 (endpoint) against baseline, using paired t test (complete pairs only) except *Chi squared test (complete pairs only) 
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Supplemental Table 1 – Hypoglycemia awareness, severe hypoglycemia, biomedical and patient-reported outcomes in MDIs vs CSII and SMBG vs RT-CGM 
comparisons at 24-month endpoint (ITT)  
 MDI CSII     P-value SMBG RT-CGM  P-value 
Hypoglycemia awareness       
    Gold score 3·5±1·7 (n=29) 3·9±2·1 (n=27) 0·35 3·8±2·0 (n=28) 3·5±1·8 (n=28) 0·57 
      Median (IQR) 3 (2-4) 4 (2-6)  4 (2-5.5) 3 (2-5)  
    Clarke score 2·3±2·3 (n=26) 2·8±1·9 (n=24) 0·39 2·7±2·2 (n=25) 2·3±2·0 (n=25) 0·51 
      Median (IQR) 1 (0-4) 3 (1.5-4.5)  3 (0-5) 2 (1-4)  
    HypoA-Q ‘Impaired Awareness’ scale 7·6±5·0 (n=29) 9·2±5·0 (n=28) 0·24 8·3±5·0 (n=29) 8·4±5·1 (n=28) 0·90 
      Median (IQR) 8 (3-11) 9.5 (4.5-12)  9 (4-11) 8.5 (3.5-12)  
Severe hypoglycemia        
Annualized rate over 24-month follow-up,  
per person/year 
0·4±0·8 (n=34) 0·4±0·9 (n=35) 0·97 0·5±1·0 (n=35) 0·3±0·6 (n=34) 0·33 
      Median (IQR) 0 (0-0.5) 0 (0-0.5)  0 (0-0.5) 0 (0-0.5)  
   Proportion affected, % 40 (n=40) 32 (n=38)   0·44* 32 (n=38) 40 (n=40)  0·44* 
HbA1c, mmol/mol 62±12 (n=37) 61±9 (n=35) 0·87 61±11 (n=36) 61±10 (n=36)  
Weight, kg 75·2±12·7 (n=39) 75·2±14·3 (n=35) 0·99 75·1±13·7 (n=39) 75·4±13·2 (n=35) 0·93 
Total daily insulin dose, u/kg 0·56±0·17 (n=25) 0·51±0·14 (n=26) 0·27 0·52±0·12 (n=27) 0·56±0·18 (n=24) 0·27 
Biochemical hypoglycemia, % time 
interstitial glucose ≤3mmol/L 
2·4±3·8 (n=30) 2·8±4·5 (n=25) 0·72 2·6±3·6 (n=27) 2·6±4·6 (n=28) 0·98 
Satisfaction with diabetes treatment: DTSQ       
    Total satisfaction 30·7±5·0 (n=29) 31·7±4·6 (n=27) 0·43 31·0±4·8 (n=31) 31·3±4·8 (n=25) 0·81 
    Perceived frequency of hyperglycemia 2·9±1·3 (n=29) 3·2±1·4 (n=28) 0·40 3·0±1·3 (n=31) 3·2±1·4 (n=26) 0·61 
    Perceived frequency of hypoglycemia 2·4±1·3 (n=29) 3·0±1·3 (n=28) 0·09 2·8±1·3 (n=31) 2·6±1·4 (n=26) 0·66 
Fear of hypoglycemia: HFS-II       
    Total 38·3±26·2 (n=23) 42·2±27·3 (n=24) 0·62 40·5±24·9 (n=24) 40·0±28·8 (n=23) 0·95 
    Behavior 18·3±10·6 (n=24) 20·4±11·8 (n=25) 0·52 18·7±8·9 (n=26) 20·0±13·5 (n=23) 0·68 
    Worry 20·6±17·5 (n=25) 22·6±17·3 (n=27) 0·69 23·1±1·.3 (n=27) 20·0±17·5 (n=25) 0·52 
Data are meanSD unless stated otherwise. Number with available data denoted by n number in parentheses.  
P-values compare MDI and CSII groups at month 24, using two-sample t test, except *X
2
 test.  
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Supplemental Table 2 – Hypoglycemia awareness, severe hypoglycemia, biomedical and patient-reported outcomes at 24-month endpoint (per protocol): insulin 
delivery modality (MDI only vs. CSII only vs. switched) and RT-CGM use (<50% of time vs ≥50% of time) 
 Insulin delivery modality throughout 24-month study (n=80) RT-CGM use (n=14) 
MDI only  
(n=10) 
Switched (MDI & 
CSII) (n=45) 
CSII only  
(n=25) 
<50% time  
(n=6) 
≥50% time  
(n=8) 
Hypoglycemia awareness      
    Gold score 2·9±1·2 (n=8) 3·6±1·9 (n=28) 3·9±2·1 (n=18) 2·8±1·9 (n=5) 3·3±2·0 (n=7) 
      Median (IQR) 3 (2-3.5) 4 (2-5) 4 (2-6) 2 (2-3) 3 (2-4) 
    Clarke score 1·4±1·9 (n=7) 2·5±2·0 (n=25) 2·8±2·2 (n=16) 1·0±1·4 (n=5) 1·8±1·7 (n=6) 
      Median (IQR) 1 (0-3) 3 (1-4) 2 (0.5-5) 0 (0-2) 1.5 (1-2) 
    HypoA-Q ‘Impaired Awareness’ 6·6±3·5 (n=8) 7·9±5·2 (n=27) 9·2±5·2 (n=20) 4·2±2·2 (n=5) 7·7±5·7 (n=7) 
      Median (IQR) 6 (3.5-10) 9 (3-11.5) 9.5 (4-11.5) 3 (3-6) 5 (3-13) 
Severe hypoglycemia      
    Annual rate over 24-month follow-up, 
per person/year 
0·2±0·5 (n=10) 0·4±0·8 (n=33) 0·5±1·0 (n=25) 0·0±0·0 (n=6) 0·3±0·4 (n=8) 
      Median (IQR) 0 (0-0.5) 0 (0-0) 0 (0-0.5) 0 (0-0) 0 (0-0.5) 
    Proportion affected, % 30 (n=10) 36 (n=39) 32 (n=25) 0 (n=6) 38 (n=8) 
HbA1c, mmol/mol 66±13 (n=9) 62±11 (n=38) 59±8 (n=23) 57±7(n=6) 56±9 (n=8) 
Weight, kg 79·0±11·6 (n=10) 75·0±13·7 (n=37) 73·8±14·2 (n=24) 73·9±13·8 (n=6) 79·9±14·3 (n=8) 
Total daily insulin dose, u/kg Data not collected 0·55±0·16 (n=30) 0·52±0·15 (n=20) 0·58±0·16 (n=5) 0·66±0·13 (n=5) 
Biochemical hypoglycemia, % time 
interstitial glucose ≤3mmol/L 
2·8±4·8 (n=10) 2·8±4·7 (n=25) 2·3±3·0 (n=18) 4·3±8·8 (n=5) 3·0±4·8 (n=6) 
Satisfaction with diabetes treatment: DTSQ      
    Total satisfaction 30·1±2·9 (n=7) 30·8±6·0 (n=28) 31·9±3·4 (n=19) 31·2±4·4 (n=5) 31·2±5·0 (n=6) 
    Perceived frequency of hyperglycemia 2·3±0·8 (n=7) 3·3±1·4 (n=29) 3·1±1·4 (n=19) 3·2±1·9 (n=5) 3·5±1·0 (n=6) 
    Perceived frequency of hypoglycemia 2·1±1·2 (n=7) 2·6±1·5 (n=29) 3·2±1·1 (n=19) 2·4±1·3 (n=5) 2·8±1·3 (n=6) 
Fear of hypoglycemia: HFS-II      
    Total 31·8±15·7 (n=6) 43·7±29·9 (n=23) 39·8±25·7 (n=17) 24·5±12·1 (n=4) 28·1±17·4 (n=7) 
    Behavior 18·3±5·9 (n=6) 18·8±12·4 (n=24) 20·7±11·4 (n=18) 15·3±6·3 (n=4) 16·4±9·0 (n=7) 
    Worry 13·5±11·2 (n=6) 26·0±19·4 (n=25) 19·1±15·5 (n=19) 15·0±15·4 (n=5) 11·7±10·1 (n=7) 
Data are meanSD unless stated otherwise. Number with available data denoted by n number in parentheses.  
No formal hypothesis testing was performed due to small numbers of observations in certain groups. 












Supplemental Figure 1. Flow diagram showing number of participants allocated at random to each intervention, completing the 
24-week RCT and completing 24-month follow-up.  
Numbers using MDI and CSII during the RCT and post-RCT follow-up are shown. No participants randomized to SMBG commenced RT-
CGM throughout the 24-month study and RT-CGM provision was not withdrawn from any participant randomized to RT-CGM (although 
not all continued active use, with 11 (30%) confirmed active users of this technology at study completion). 
